Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman purchased 98,000 shares of the business’s stock in a transaction dated Monday, November 21st. The stock was bought at an average price of $0.43 per share, with a total value of $42,140.00. Following the acquisition, the chief executive officer now directly owns 79,111 shares in the company, valued at $34,017.73. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 5.33% during trading on Tuesday, reaching $0.38. 774,439 shares of the company’s stock traded hands. The stock’s market capitalization is $9.83 million. The company has a 50-day moving average of $0.54 and a 200 day moving average of $1.62. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $0.37 and a 12 month high of $7.95.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.05. On average, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post ($1.59) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Several institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. increased its position in shares of Tonix Pharmaceuticals Holding Corp. by 279.4% in the second quarter. Franklin Resources Inc. now owns 1,610,045 shares of the company’s stock valued at $3,204,000 after buying an additional 1,185,664 shares during the period. Opaleye Management Inc. purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter valued at about $1,592,000. Vanguard Group Inc. increased its position in shares of Tonix Pharmaceuticals Holding Corp. by 1.5% in the second quarter. Vanguard Group Inc. now owns 707,065 shares of the company’s stock valued at $1,407,000 after buying an additional 10,531 shares during the period. Sabby Management LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. by 52.0% in the second quarter. Sabby Management LLC now owns 585,914 shares of the company’s stock valued at $1,166,000 after buying an additional 200,518 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter valued at about $290,000. 22.04% of the stock is owned by institutional investors.

TNXP has been the subject of several recent research reports. Roth Capital downgraded shares of Tonix Pharmaceuticals Holding Corp. from a “buy” rating to a “neutral” rating in a report on Wednesday, September 7th. Oppenheimer Holdings Inc. downgraded shares of Tonix Pharmaceuticals Holding Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 7th. Finally, Cantor Fitzgerald downgraded shares of Tonix Pharmaceuticals Holding Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, September 7th.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/22/tonix-pharmaceuticals-holding-corp-tnxp-ceo-seth-lederman-purchases-98000-shares.html.

5 Day Chart for NASDAQ:TNXP

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.